Compare Fidelity National Information Servcs Inc (FIS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Novo Nordisk A/S — how do they compare? Fidelity National Information Servcs Inc trades at $41.8 (market cap $22.05B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 9.4× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4.12%). Which is the better fit depends on your goals.
| FIS | NVO | |
|---|---|---|
Market Cap | $22.05B | $207.85B |
Sector | Technology | Health |
52-Week High | $72.77 | $63.98 |
52-Week Low | $37.72 | $35.29 |
Enterprise Value | $42.56B | $222.55B |
Dividend Yield | 4.12% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.51, down 0.61% today. The stock shows mixed signals with a bearish technical trend but strong fundamentals, including a low P/E of 6.57 and robust ROE of 22.33%. Recent Q2 2026 earnings beat expectations, driven by Banking Solutions growth, though full-year guidance was trimmed. Positive news includes global platform expansions in APAC and industry recognition for treasury software.
The outlook is cautiously optimistic. Attractive valuation and profitability metrics present an opportunity, but risks include execution challenges in Capital Markets and competitive pressures. Analyst consensus is strongly Buy with a $50.18 price target, suggesting significant upside potential from current levels if growth initiatives succeed.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
